Related by context. All words. (Click for frequent words.) 61 mg/m2/day 61 mg m² 60 refractory DLBCL 60 refractory AML 60 CLL SLL 60 relapsed refractory multiple myeloma 59 #mg QD [002] 59 bendamustine 59 VELCADE melphalan 59 remission induction 59 refractory NSCLC 58 PEG IFN 58 gemcitabine cisplatin 57 refractory multiple myeloma 57 treatment naive genotype 57 refractory CLL 57 refractory metastatic colorectal cancer 57 refractory chronic lymphocytic 57 piperacillin tazobactam 57 atazanavir ritonavir 57 prior chemotherapy regimens 57 leukemia AML 56 dosing cohorts 56 gemcitabine carboplatin 56 dosing cohort 56 dose cohort 56 metastatic CRC 56 mg/m2 dose 56 Arzerra ofatumumab 56 ZACTIMA 56 BARACLUDE ® 56 refractory acute myeloid 56 rFSH 56 mitoxantrone plus 55 #mg QD [001] 55 dasatinib Sprycel ® 55 dose melphalan 55 relapsed MM 55 refractory myeloma 55 refractory cutaneous T 55 refractory Hodgkin lymphoma 55 refractory indolent NHL 55 refractory acute promyelocytic 55 relapsed refractory 55 Fludarabine 55 heavily pretreated patients 55 #mg/m# [002] 55 refractory CTCL 55 CHOP chemotherapy 55 metastatic malignant 55 refractory indolent non 55 huN# DM1 55 CIMZIA TM 55 ribavirin RBV 55 ara C 55 alfa 2a 55 Cloretazine ® 54 #mg/m# [001] 54 Phase IIb trials 54 Hycamtin ® 54 Doxil ® 54 8mg/kg 54 lymphoid malignancies 54 EOquin TM 54 ASCT 54 achieved ACR# 54 HBeAg + 54 evaluating Xcytrin 54 evaluable subjects 54 Pemetrexed 54 ug kg 54 dose cohorts 54 CRp 54 receptor tyrosine kinase inhibitor 54 q#d 54 achieved CCyR 54 MabCampath 54 virologic response EVR 54 CLARITY study 54 mg kg dose 54 metastatic renal cell 54 stage IIIb IV 54 relapsing multiple sclerosis 54 dose dexamethasone 54 chemoradiation therapy 54 sunitinib malate 54 KRAS mutations occur 54 Bezielle 53 recurrent NSCLC 53 antithymocyte globulin 53 trial evaluating Prochymal 53 tumors GIST 53 chlorambucil 53 stage IIIB 53 relapsed CLL 53 mg qd 53 telaprevir dosed 53 MabThera Rituxan 53 certolizumab 53 #mg BID [001] 53 ascending doses 53 systemic ALCL 53 4mg/kg 53 IRESSA 53 adjuvant cisplatin 53 tipranavir r 53 dacarbazine DTIC 53 mcg kg 53 forodesine 53 refractory APL 53 doxorubicin cyclophosphamide 53 non splenectomized 53 lymphoid blast 53 MCyR 53 anthracyclines taxanes 53 Omacetaxine 53 metastatic hormone refractory 53 measurable tumor regressions 53 HBeAg negative patients 53 pegylated interferon alpha 52 phase Ib 52 Irinotecan 52 PegIFN RBV 52 previously untreated follicular 52 oblimersen 52 leukemia CLL 52 biliary tract cancer 52 azacitidine 52 QD dosing 52 Pegasys ® 52 Aloxi injection 52 plus prednisone prednisolone 52 mg BID 52 pegIFN 52 Diffuse Large B 52 low dose cytarabine 52 Peg IFN 52 TORISEL 52 refractory lymphoma 52 oral vancomycin 52 Pharmacokinetics PK 52 Myelodysplastic Syndrome MDS 52 anthracycline taxane 52 peginterferon alpha 2a 52 peg interferon 52 dexamethasone Decadron 52 mRCC 52 baseline LDH 52 Median PFS 52 HSCT 52 dose escalation phase 52 undetectable HBV DNA 52 cyclophosphamide chemotherapy 52 lumiliximab 52 Amrubicin 52 refractory HL 52 adjunctive placebo 52 Elitek 52 placebo intravenously 52 boosted protease inhibitor 52 vandetanib 52 doxorubicin docetaxel 52 oral ridaforolimus 52 docetaxel Taxotere 52 refractory follicular lymphoma 52 partial remissions 52 HCV RESPOND 2 52 lenalidomide Revlimid R 52 interferon ribavirin 52 untreated multiple myeloma 52 dasatinib Sprycel 52 Fludara 51 MGd 51 HBeAg seroconversion 51 ritonavir boosted 51 oral allopurinol 51 blastic phase 51 carboplatin paclitaxel 51 DOXIL ® 51 ELOXATIN 51 cytarabine daunorubicin 51 #/#mg 51 refractory PTCL 51 unresectable Stage III 51 cell lymphoma CTCL 51 Follicular Lymphoma 51 rapid virologic response 51 somatostatin analog 51 refractory ALCL 51 dose escalation 51 metastatic GIST 51 Cloretazine 51 briakinumab 51 axitinib 51 ErbB2 positive 51 mcg albinterferon alfa 2b 51 heavily pretreated 51 cetuximab Erbitux R 51 opioid induced constipation OIC 51 metastatic gastric 51 total thyroidectomy 51 null responder HCV 51 sorafenib Nexavar 51 advanced carcinoid 51 abiraterone acetate 51 pegfilgrastim 51 imatinib Gleevec ® 51 desvenlafaxine succinate 51 plus gemcitabine 51 EGFR expressing 51 HBeAg positive patients 51 metastatic renal cell carcinoma 51 antibody MAb 51 MAGE A3 ASCI 51 de novo kidney transplant 51 fluticasone salmeterol 51 peginterferon alfa 2a 51 anthracycline containing 51 Traficet EN 51 receiving highly emetogenic 51 docetaxel chemotherapy 51 AUC0 51 HBeAg negative 51 recurrent metastatic 51 erlotinib Tarceva ® 51 relapsed 51 complete cytogenetic response 51 5-FU/LV 51 CAELYX 51 REYATAZ R 51 relapsed multiple myeloma 51 prostate cancer HRPC 51 telaprevir dosing 51 adefovir treated 51 LEXIVA r 51 symptomatic BPH 51 remission CR 51 Seliciclib 51 Torisel 51 adalimumab Humira 51 RoACTEMRA 51 pomalidomide 51 relapsing remitting MS RRMS 51 mycophenolate mofetil MMF 51 alvespimycin 51 oral rivaroxaban 51 nab paclitaxel 51 Sprycel dasatinib 50 anagrelide 50 neoadjuvant treatment 50 octreotide 50 comparator arm 50 recurrent malignant glioma 50 Pegasys plus Copegus 50 dosed orally 50 PEGINTRON TM 50 pegylated interferon alfa 2a 50 clodronate 50 randomized #:#:# 50 Flu Cy 50 metastatic sarcoma 50 neoadjuvant 50 IV NSCLC 50 induce remission 50 Cutaneous T 50 TMC# r 50 histologically confirmed 50 relapsed Hodgkin lymphoma 50 plus methotrexate 50 autoantibody positive 50 vinorelbine 50 phase IIb study 50 IMGN# 50 metastatic bladder 50 mesalamine granules 50 CCyR 50 Annamycin 50 ALT flares 50 interferon alfa 2a 50 Decitabine 50 interquartile range 50 plus dexamethasone 50 biochemical relapse 50 AZT zidovudine Retrovir 50 nonmetastatic 50 HER2 positive metastatic breast 50 leukemia ALL 50 rapid virological response 50 unresectable stage 50 Mitoxantrone 50 Triapine R 50 TTF Therapy 50 trabectedin 50 CR CRu 50 everolimus tablets 50 dose dose escalation 50 HGS# 50 Stage IIB 50 platinum refractory 50 underwent liver transplantation 50 HCV infected 50 Cimzia TM 50 vinflunine 50 CANCIDAS 50 BEACOPP 50 macroglobulinemia 50 dose escalation clinical 50 virological failure 50 mitoxantrone chemotherapy 50 Dacogen injection 50 dacarbazine 50 ACR# responses 50 evaluable patients 50 glufosfamide 50 cisplatin chemotherapy 50 tapentadol ER 50 cutaneous T 50 log# IU mL 50 APTIVUS r 50 Jevtana 50 primary hypercholesterolemia 50 rindopepimut 50 disease progression TTP 50 mg BID dose 50 FOLPI 50 alefacept 50 multiple myeloma MM 50 Velcade bortezomib 49 Folfox 49 dose escalation trial 49 FOLFIRI alone 49 LIALDA 49 RRMS patients 49 SCCHN 49 baminercept 49 hematologic toxicity 49 Non Hodgkin 49 recurrent glioblastoma multiforme 49 Uricase PEG 49 log# reduction 49 fallopian tube carcinoma 49 GnRH antagonist 49 cGy 49 pertuzumab 49 Taxotere ® 49 virologic suppression 49 gemcitabine Gemzar ® 49 ZOLINZA 49 EDSS scores 49 CRu 49 EGFR TKI 49 care regimens CCR 49 ribavirin therapy 49 EURIDIS 49 Omnitarg 49 gemcitabine chemotherapy 49 sorafenib Nexavar ® 49 rituximab refractory 49 IFN alfa 49 tipranavir 49 methotrexate monotherapy 49 adriamycin 49 bortezomib refractory 49 sustained virological response 49 pegylated interferon alpha 2a 49 mcg kg min 49 HGS ETR1 49 subcutaneous enoxaparin 49 fallopian tube cancers 49 patients evaluable 49 doxorubicin HCl liposome injection 49 KRAS mutant tumors 49 venlafaxine XR 49 Tarceva erlotinib 49 temsirolimus 49 Relapsed Refractory 49 neurologic progression 49 Rituxan rituximab 49 advanced NSCLC 49 detectable HCV RNA 49 pegylated liposomal doxorubicin 49 ABVD 49 cytoreduction 49 Acute Myelogenous Leukemia AML 49 methotrexate MTX 49 paclitaxel Taxol R 49 randomized #:# 49 estramustine 49 subcutaneous methylnaltrexone 49 mg/m2 49 SVR# 49 sunitinib Sutent ® 49 phase IIb clinical 49 Myelodysplasia 49 unresectable locally advanced 49 virological response 49 Advagraf 49 Cinacalcet HCl 49 #mg ATC 49 hepatic metastases 49 timepoints 49 viral kinetics 49 infusional 5-FU/LV 49 darunavir ritonavir 49 cytogenetic responses 49 Stage IIIB IV 49 acute myeloid 49 virologic failure 49 fludarabine 49 recurrent GBM 49 trastuzumab Herceptin R 49 efavirenz EFV 49 divalproex sodium 49 sunitinib 49 Vidaza azacitidine 49 microg 49 immunomodulatory therapy 49 SPRYCEL ® 49 papillary renal cell carcinoma 49 relapsed ovarian cancer 49 genotypic resistance 49 Aptivus ® 49 debulking surgery 49 plus prednisone 49 dasatinib 48 adjuvant tamoxifen 48 ACR# response 48 pamidronate 48 mapatumumab 48 VGPR 48 relapsed acute myelogenous 48 refractory systemic ALCL 48 cyclophosphamide methotrexate 48 RITUXAN 48 progression TTP 48 Acute Myeloid Leukaemia AML 48 docetaxel 48 Hazard Ratio 48 postintervention 48 refractory ovarian cancer 48 Gleevec imatinib mesylate 48 PegIntron 48 valopicitabine 48 ER CHOP 48 docetaxel Taxotere R 48 cytotoxic therapy 48 vidofludimus 48 μmol L 48 taxane refractory 48 ofatumumab 48 unresectable 48 YONDELIS 48 galiximab 48 weekly subcutaneous injections 48 antiretroviral naïve 48 IV melanoma 48 Telintra 48 fluorouracil 48 refractory colorectal cancer 48 myelodysplastic syndrome MDS 48 undetectable HCV RNA 48 chemotherapy docetaxel 48 severe oral mucositis 48 FOLFOX6 48 FOLFIRI 48 IIa trial 48 % CI #.#-#.# [007] 48 Acute Myeloid Leukemia AML 48 trastuzumab Herceptin ® 48 μg kg 48 CR nPR 48 stage IIIb 48 IIa clinical trial 48 remitting MS 48 elotuzumab 48 achieved PASI 48 pediatric acute lymphoblastic 48 PREZISTA r 48 plasma concentration Cmax 48 noninferiority 48 naïve HCV 48 peginterferon alfa 2b 48 % Confidence Interval 48 systemic anaplastic large 48 B CLL 48 mCRC patients 48 ACTEMRA TM 48 DAS# remission 48 recurrent glioblastoma 48 pegylated interferon peg IFN 48 untreated metastatic colorectal 48 corticosteroid dose 48 chemoradiotherapy 48 underwent surgical resection 48 thalidomide Thalomid 48 HBeAg positive 48 HRPC 48 Hodgkin lymphoma HL 48 BENICAR 48 FOLFOX4 48 dose regimens 48 methotrexate therapy 48 PNP inhibitor 48 intermittent dosing 48 HCV SPRINT 48 DLTs 48 decitabine 48 Epirubicin 48 adalimumab 48 FOLFOX chemotherapy 48 iniparib BSI 48 Remissions 48 tocilizumab 48 goserelin 48 paclitaxel carboplatin 48 untreated AML 48 NMIBC 48 metastatic RCC 48 adjuvant radiation 48 median CD4 48 basiliximab 48 Free Survival PFS 48 rufinamide 48 Genasense 48 indolent NHL 48 HERCEPTIN 47 PASI scores 47 monotherapy 47 phase IIb trial 47 DMARD therapy 47 non metastatic osteosarcoma 47 peg IFN 47 metastatic SCCHN 47 MDS AML 47 complete remissions 47 resistant hormone refractory 47 ORAL HYCAMTIN 47 recurrent genital herpes 47 placebo dexamethasone 47 administered subcutaneously 47 -#.# log# 47 Gemzar ® 47 androgen suppression 47 Phase 1b trial 47 follicular lymphomas 47 relapsed AML 47 refractory systemic anaplastic 47 receiving golimumab 47 chronic HCV genotype 47 KRN# 47 5FU 47 medullary thyroid cancer 47 Natalizumab 47 Telcyta 47 CYT# potent vascular disrupting 47 MoxDuo TM IR 47 cetuximab Erbitux ® 47 lopinavir r 47 etoposide 47 cabazitaxel 47 moderate renal impairment 47 #mg/day [002] 47 Navelbine ® 47 efficacy endpoint 47 FluCAM 47 dosing intervals 47 TMC# C# 47 glycoprotein GP IIb IIIa 47 idiopathic thrombocytopenic purpura 47 EGFR expressing mCRC 47 EGFR mutation positive 47 Acute Decompensated Heart Failure 47 bevacizumab Avastin ® 47 TACE 47 ALT elevations 47 RECIST criteria 47 chemotherapy cisplatin 47 cilengitide 47 castrate resistant 47 Herceptin trastuzumab 47 imatinib mesylate Gleevec 47 Phase IIa trial 47 RAEB 47 leukemia APL 47 OHR/AVR# 47 follicular lymphoma FL 47 Increlex R 47 cell acute lymphoblastic 47 postoperative chemotherapy 47 Ceflatonin 47 abatacept 47 pemetrexed 47 mcg dose 47 active comparator 47 lymphoma CTCL 47 diagnosed GBM 47 DAS# CRP 47 5-fluorouracil/leucovorin 47 ofatumumab HuMax CD# 47 Phase Ib 47 AML acute myeloid 47 Mylotarg 47 VFEND 47 cell chronic lymphocytic 47 romiplostim 47 pT3 47 lapatinib Tykerb 47 KRAS wild 47 alanine aminotransferase ALT 47 pegylated interferon alfa 47 non myeloid malignancies 47 fludarabine cyclophosphamide 47 Sutent sunitinib 47 underwent resection 47 placebo controlled clinical trials 47 median PFS 47 iniparib 47 alemtuzumab treated 47 nilotinib Tasigna ® 47 myelofibrosis MF 47 allogeneic stem cell 47 Onrigin 47 receiving VICTRELIS 47 achieved sustained virological 47 CVP chemotherapy 47 EBRT 47 fluoxetine paroxetine 47 nonmyeloablative 47 adjuvant radiotherapy 47 eculizumab 47 lumbar spine BMD 47 irinotecan containing 47 lymphocyte count 46 Myelodysplastic Syndrome 46 ELACYT 46 taxotere 46 IFN α 46 dose cyclophosphamide 46 BRIM3 46 AGILECT R 46 cells mcL 46 weekly intravenous infusions 46 neoadjuvant chemotherapy 46 relapsed indolent NHL 46 plus MTX 46 cytogenetic response 46 MoxDuo IR 46 Waldenstrom macroglobulinemia 46 ixabepilone 46 Zytiga 46 relapsed acute lymphoblastic 46 peginterferon alfa 46 advanced medullary thyroid 46 J Clin Oncol 46 myelodysplastic syndromes MDS 46 metastatic malignant melanoma 46 CML CP 46 epirubicin 46 seropositive patients 46 registrational 46 stage IIIB IV 46 experienced virologic failure 46 μg mL 46 lintuzumab 46 oxycodone CR 46 REVLIMID lenalidomide 46 superficial bladder cancer 46 nitazoxanide 46 EDSS score 46 severe exacerbations 46 Phase IIa clinical 46 chronic GVHD 46 acute GvHD 46 DLBCL 46 bladder carcinoma 46 Phase 2b study 46 Relapsed 46 cyclophosphamide doxorubicin vincristine 46 hepatocellular carcinoma HCC 46 relapsed myeloma 46 Maximum Tolerated Dose 46 phase 2a 46 relapsed GBM 46 CsA 46 mL/min/#.# m2 46 VIDAZA 46 demonstrated antitumor activity 46 Femara letrozole 46 diagnosed multiple myeloma 46 cancer neuroendocrine tumor 46 rALLy 46 icatibant 46 recurrent VTE 46 antiretroviral naive 46 TREANDA 46 Hepatocellular Carcinoma HCC 46 anti TNF alpha 46 cutaneous T cell 46 liver histology 46 lymphocytosis 46 IV metastatic melanoma 46 prior nephrectomy 46 advanced metastatic renal 46 plus ribavirin 46 irinotecan chemotherapy 46 velaglucerase alfa 46 Solid Tumors criteria 46 localized renal 46 preoperative chemotherapy 46 androgen blockade 46 amrubicin 46 gefitinib Iressa 46 follicular Non Hodgkin 46 Pixantrone 46 melphalan 46 Revlimid lenalidomide 46 operable breast cancer 46 eosinophilic asthma 46 immune thrombocytopenic purpura ITP 46 mitoxantrone 46 alkylating agent 46 ACZ# 46 Phase 1b 46 cis retinoic acid 46 oral clodronate 46 pmol L 46 biologic therapy 46 follicular NHL 46 FOLFOX 46 surgical debulking 46 Etanercept 46 MADRS score 46 chronic plaque psoriasis 46 Cmax 46 lamivudine monotherapy 46 dose regimen 46 μg liter 46 enzastaurin 46 cytotoxic chemotherapy 46 sustained virologic response 46 metastatic pancreatic cancer 46 p#HER# positive 46 Clolar 46 darbepoetin alfa 46 Phase 2a trial 45 Score DAS# 45 cytarabine 45 neutropenic 45 haematologic 45 elevated ALT 45 pT2 45 standard chemotherapy regimens 45 MVax R 45 Gleevec resistant 45 resectable 45 total abdominal hysterectomy 45 colorectal cancer liver metastases 45 peginterferon 45 RGT arm 45 interferon alfa 2b 45 FOLOTYN 45 #.#/#.# mmHg [001] 45 anti leukemic 45 Phase 2a clinical 45 papillary thyroid carcinoma 45 GnRH agonist 45 relapsing remitting multiple sclerosis 45 gastrointestinal stromal tumor GIST 45 metastatic lung cancer 45 HAM D# scores 45 AP# [003] 45 IV malignant melanoma 45 taxane chemotherapy 45 annualized relapse 45 nucleoside naive 45 RG# [001] 45 chronic myeloid leukemia CML 45 visilizumab 45 CVP cyclophosphamide vincristine 45 partial onset seizures 45 Ph + 45 bortezomib 45 regorafenib 45 refractory metastatic 45 afatinib 45 lupus nephritis 45 nonsmall cell lung cancer 45 metastatic NSCLC 45 jana.mlcochova @ thomson.com 45 Toxicities 45 pegylated interferon 45 castrate resistant prostate cancer 45 NNRTI 45 complete cytogenetic 45 diagnosed Ph + 45 Acute Myeloid Leukemia 45 PKC# 45 mucosal healing 45 ALT elevation 45 imatinib therapy 45 metastatic kidney 45 urinary N telopeptide 45 standard chemotherapy regimen 45 rimonabant #mg 45 plasma uric acid 45 refractory chronic myeloid 45 pCR 45 Newly Diagnosed Multiple Myeloma 45 vismodegib 45 Phase IIa 45 Cytoxan 45 % CI #.#-#.# [008] 45 pancreatic NET 45 virological suppression 45 steroid refractory ulcerative 45 venlafaxine ER 45 calcineurin inhibitor 45 oral diclofenac 45 splenectomized patients 45 Hodgkin lymphoma NHL 45 #Gy 45 clinically meaningful improvement 45 Ribavirin 45 HCV replicon 45 CHOP cyclophosphamide doxorubicin vincristine 45 follicular non 45 decompensated liver disease 45 Complete Response CR 45 FORTIS M 45 COU AA 45 Mantle Cell Lymphoma 45 oral methylnaltrexone 45 Alemtuzumab 45 mycophenolate mofetil 45 relapsed leukemia 45 Partial Response 45 Bortezomib 45 Refractory Hodgkin Lymphoma 45 ovarian carcinoma 45 Response Evaluation Criteria 45 lamivudine refractory patients 45 NOXAFIL Oral Suspension 45 chronic HCV 45 eribulin 45 metastatic castration resistant 45 B Cell Lymphoma 45 metastatic renal 45 COPAXONE ® 45 Scale EDSS 45 acute gout flares 45 Phase 2a 44 gastrointestinal stromal tumors GIST 44 chemo radiotherapy 44 idarubicin 44 diagnosed glioblastoma multiforme 44 Tmax 44 endoscopic remission 44 abatacept Orencia 44 celgosivir 44 atherothrombotic events 44 dimeglumine 44 Tamibarotene 44 molecular remissions 44 FOLFOX regimen 44 taxane 44 basal cell carcinoma BCC 44 relapsed Acute Myeloid 44 visceral metastases 44 velafermin 44 6 mercaptopurine 44 Xcytrin 44 advanced metastatic prostate 44 potentially hepatotoxic 44 serum HCV RNA 44 azathioprine 44 TGZ 44 hepatic encephalopathy HE 44 colorectal liver metastases 44 refractory gout 44 ponatinib 44 anthracycline therapy 44 relapsed refractory ALL 44 metastatic CRPC 44 ZEVALIN 44 doublet chemotherapy 44 nM 44 temozolomide 44 acute myelogenous leukemia AML 44 TMC# [001] 44 linezolid 44 Ann Intern Med 44 alanine transaminase ALT 44 DMARD 44 G CSF 44 TURBT 44 Glioblastoma Multiforme 44 p = NS 44 NSCLC 44 acute leukemias 44 imetelstat 44 LHRH receptor positive 44 gastrointestinal stromal tumors 44 progressive PsA 44 refractory follicular 44 clinically meaningful improvements 44 protease inhibitor PI 44 Major Depressive Disorder MDD 44 null responders 44 Erlotinib 44 PSADT 44 refractory peripheral T 44 durable remissions 44 thymoma 44 Epratuzumab 44 chronic lymphocytic leukemia CLL 44 systemic ALCL patients 44 docetaxel prednisone 44 oral COTI 44 paraprotein 44 refractory Hodgkin 44 VELCADE 44 aripiprazole 44 posttreatment 44 bevacizumab 44 liver metastases 44 bipolar mania 44 elacytarabine 44 lymphocytic leukemia 44 Marqibo 44 Solorel 44 cell lymphoma PTCL 44 tumor regression 44 CD3 + 44 phase Ph + 44 glioblastoma multiforme GBM 44 lenalidomide 44 Partial Responses 44 hemagglutination inhibition 44 HER2 negative 44 taxane chemotherapy administered 44 ispinesib administered 44 myeloproliferative disorder 44 nilotinib 44 topotecan 44 dirucotide MBP# 44 refractory SCLC 44 neoadjuvant therapy 44 carcinoma mCRC 44 Chronic Myeloid Leukemia 44 pharmacodynamic PD 44 resistant ovarian cancer 43 keloid scarring 43 pancreatic carcinoma 43 dosing regimens 43 Zevalin 43 HCV genotype 1 43 deletion 5q 43 imipenem 43 Medullary thyroid cancer 43 CZP 43 T1c 43 laparoscopic radical nephrectomy 43 achieved sustained virologic 43 metastatic colorectal cancer 43 unique alkylating agent 43 imatinib mesylate 43 chemoradiation 43 unfavorable cytogenetics 43 DMARDs 43 myelofibrosis 43 irinotecan 43 hepatitis C genotype 43 AUCs 43 interferon alfa 43 Double Blind Randomized 43 ankylosing spondylitis AS 43 febrile neutropenia 43 oxaliplatin 43 Cariprazine 43 sorafenib 43 MIC# [001] 43 mCRC 43 Ph + CP 43 T Cell Lymphoma 43 gout flares 43 metastatic medullary thyroid 43 bevacizumab Avastin 43 essential thrombocythemia 43 Phase 2b clinical 43 acute myelogenous 43 clofarabine 43 Chronic Myelogenous Leukemia CML 43 lamivudine 43 molindone 43 Pharmacokinetic 43 capecitabine 43 peritoneal carcinomatosis 43 metastatic HRPC 43 Kaplan Meier estimates